| Therapeutic | Relatlimab |
| Target | LAG3 |
| Heavy Chain | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS |
| Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (August '23) | Phase-II/III |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2018 |
| INN Year Recommended | 2019 |
| Companies Involved | Bristol-Myers Squibb, Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Conditions Approved | na |
| Conditions Active | Malignant melanoma, Colorectal cancer, Gastric cancer, Renal cell carcinoma, Solid tumours, Oesophageal cancer, Glioblastoma |
| Conditions Discontinued | Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Hodgkin's disease, Mantle-cell lymphoma, Non-Hodgkin's lymphoma |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
